Random presentations that I found interesting and promising from this year's Society for Neuroscience meeting will be posted here. A bonus this year: funding information was provided with most (if not all) presentations. (Name in parentheses is the person who presented at SfN.)
This first post will cover research funded by the PVA.
This first post will cover research funded by the PVA.
Novel compounds that overcome inhibition of CNS regeneration (Andrea L Peterson)
The failure of central nervous system (CNS) neurons to regenerate following spinal cord injury (SCI) leads to irreversible paralysis and sensory deficits. Traumatic insults to the spinal cord lead to the deposition of inhibitory myelin debris and the formation of a glial scar, which contains a large number of regeneration inhibitors. Prominent among these inhibitors is a family of astrocyte produced proteoglycans known as chondroitin sulfate proteoglycans (CSPGs). Attempts to achieve regeneration of long axon tracts by overcoming inhibitory signals from myelin and CSPGs have met with limited success, partially owing to a lack of detailed knowledge about the signaling mechanisms underlying inhibitory CSPG signals. One way to advance our knowledge and promote novel therapies for SCI is to identify chemical compounds with the ability to overcome regeneration inhibition.
Our lab has undertaken a “chemical genetics” approach, screening a library of novel triazine compounds to identify those that promote neurite growth on inhibitory substrates. We initially identified four “hit” compounds based on their ability to increase neurite outgrowth on an inhibitory substrate of CNS myelin. Interestingly, these compounds also increase neurite outgrowth from several different classes of CNS neurons on a substrate of inhibitory CSPGs, suggesting that they act through a signaling pathway that is common to both classes of inhibitors. Most excitingly, one of the compounds, F05, promotes acute regeneration of severed dorsal column axons in vivo. Studies of potential mechanisms revealed that the compounds do not act through cAMP, protein kinase C, or the EGF receptor. However, compound F05 does affect microtubule dynamics in cultured hippocampal neurons, suggesting a potential mechanism through which regeneration could be affected. Elucidation of the mechanism of action of these compounds should provide insight into mechanisms of regeneration inhibition, and may lead to novel therapeutic strategies for SCI.
Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the cns (John Dill)
Axonal regeneration is minimal after the CNS injuries in adult mammals and the medical treatments to recover the neurological loss due to axon disconnection are extremely limited. The nonpermissive environment and reduced intrinsic growth capacity are principally attributed to the failure for axonal elongation. In this report, we studied the role of glycogen synthase kinase-3 (GSK-3) inactivation on neurite and axon growth of adult neurons via combined in vitro and in vivo approaches. We found that the major CNS inhibiting substrates including chondroitin sulfate proteoglycans (CSPG) could inactivate protein kinase B (Akt) and activate GSK-3β signals in neurons. GSK-3 inactivation with pharmacologic inhibitors enhances neurite outgrowth of dorsal root ganglion neurons derived from adult mice or cerebellar granule neurons from postnatal rodents cultured on CNS inhibitors. Application of GSK-3 inhibitors stimulates axon formation and elongation of mature neurons whether in presence or absence of inhibitory substrates. Systemic application of GSK-3 inhibitor lithium to spinal cord-lesioned rats suppresses the activity of this kinase around lesion. Treatments with GSK-3 inhibitors including a clinical dose of lithium to rats with thoracic spinal cord transection or contusion injuries induce significant descending corticospinal and serotonergic axon sprouting in caudal spinal cord and promote locomotor functional recovery. Our studies suggest that GSK-3 signal is an important therapeutic target for promoting functional recovery of adult CNS injuries and that administration of GSK-3 inhibitors may facilitate the development of an effective treatment to white matter injuries including spinal cord trauma given the wide use of lithium in humans.
The temporal expression of S100B and GFAP in cerebrospinal fluid following acute human spinal cord injury (Cody M Mann)
Background: Glial fibrillary acidic protein (GFAP) and S100B have been used as biological markers of injury severity in traumatic brain injury. However, little is known about the temporal release of GFAP and S100B after spinal cord injury in humans or about the correlation of these protein levels with injury severity.
Objective: To evaluate the concentration of S100B and GFAP within the cerebrospinal fluid (CSF) of human patients with acute SCI, and document the temporal pattern of change over 72 hours.
Methods: Human patients within 48 hours of sustaining an SCI were enrolled in a clinical trial in which a lumbar intrathecal catheter was inserted to drain CSF. CSF samples were drawn at 8 hour intervals, centrifuged, and frozen at the bedside. The drains were left in for 72 hours. An ELISA kit was used to evaluate the level of S100B and GFAP in the CSF.
Results: S100B and GFAP were elevated within 24 hours after SCI. The concentrations of these factors decreased over the 72 hours that the drain was inserted.
Discussion: This study describes the temporal release of S100B and GFAP after human spinal cord injury. This information may serve as a tool to help with the classification of injury severity and prediction of neurologic outcome, and may also be useful as a biological method of monitoring the effect of drug therapies for SCI.
Increased expression of 5'-ectonucleotidase and the adenosine A2B receptor in chronic spinal cord injury (Raymond J Grill)
Trauma to the spinal cord destroys or alters tissue through mechanical and biochemical mechanisms. These injury-induced alterations in the neuronal, glial and vascular environment include glial scarring, failed regenerative growth of motor pathways and the potential for development of devastating neuropathic pain conditions. Nucleotides and nucleosides are important mediators of cellular activity in both normal and pathological conditions. Adenosine is one such modulator that is normally present in low concentrations in the extracellular space where it acts through four G-protein-linked receptors. Injury has been shown to significantly elevate extracellular levels of adenosine through several mechanisms including the metabolism of cell-released ATP via enzymes called ectonucleotidases, the release of intracellular stores through specific transporters, and uncontrolled release through membrane disruption. Following injury, the role of adenosine has generally been considered to be benign; producing neuroprotective effects. However, injury-induced adenosine has also been linked with astroglial activation, influencing astrocyte proliferation and morphological characteristics of gliosis (Liberto et al. 2004). Adenosine levels increase dramatically, but transiently, following SCI (McAdoo et al, 2000), hitting a peak between 30 to 60 minutes post-injury, then returning to baseline levels. Despite the transient increase in adenosine following SCI, we have recently detected elevated immunoreactivity (-IR) of the low-affinity adenosine A2B receptor co-localized with the astrocytic marker GFAP in- and around the site of spinal contusion in adult rats one-to-three months post-SCI. A2B-IR was also detected in cells of the central canal bordering the cavity. Interestingly, A2B+/GFAP+ cells appear to stream from the canal region to the contusion cavity. Elevated 5’-ectonucledotidase (5-NT)-IR co-localized to both reactive astrocytes and blood vessels in- and around the lesion cavity in chronic SCI. While the presence of elevated extracellular adenosine has yet to be demonstrated in the chronically-injured cord, our current data suggest that adenosine may play a role in influencing pathological processes such as the glial scar in chronic SCI.
The failure of central nervous system (CNS) neurons to regenerate following spinal cord injury (SCI) leads to irreversible paralysis and sensory deficits. Traumatic insults to the spinal cord lead to the deposition of inhibitory myelin debris and the formation of a glial scar, which contains a large number of regeneration inhibitors. Prominent among these inhibitors is a family of astrocyte produced proteoglycans known as chondroitin sulfate proteoglycans (CSPGs). Attempts to achieve regeneration of long axon tracts by overcoming inhibitory signals from myelin and CSPGs have met with limited success, partially owing to a lack of detailed knowledge about the signaling mechanisms underlying inhibitory CSPG signals. One way to advance our knowledge and promote novel therapies for SCI is to identify chemical compounds with the ability to overcome regeneration inhibition.
Our lab has undertaken a “chemical genetics” approach, screening a library of novel triazine compounds to identify those that promote neurite growth on inhibitory substrates. We initially identified four “hit” compounds based on their ability to increase neurite outgrowth on an inhibitory substrate of CNS myelin. Interestingly, these compounds also increase neurite outgrowth from several different classes of CNS neurons on a substrate of inhibitory CSPGs, suggesting that they act through a signaling pathway that is common to both classes of inhibitors. Most excitingly, one of the compounds, F05, promotes acute regeneration of severed dorsal column axons in vivo. Studies of potential mechanisms revealed that the compounds do not act through cAMP, protein kinase C, or the EGF receptor. However, compound F05 does affect microtubule dynamics in cultured hippocampal neurons, suggesting a potential mechanism through which regeneration could be affected. Elucidation of the mechanism of action of these compounds should provide insight into mechanisms of regeneration inhibition, and may lead to novel therapeutic strategies for SCI.
- Funded by:
- Veterans of America, Grant # 2445
- Craig H. Neilsen Foundation
- Wallace H. Coulter Foundation
Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the cns (John Dill)
Axonal regeneration is minimal after the CNS injuries in adult mammals and the medical treatments to recover the neurological loss due to axon disconnection are extremely limited. The nonpermissive environment and reduced intrinsic growth capacity are principally attributed to the failure for axonal elongation. In this report, we studied the role of glycogen synthase kinase-3 (GSK-3) inactivation on neurite and axon growth of adult neurons via combined in vitro and in vivo approaches. We found that the major CNS inhibiting substrates including chondroitin sulfate proteoglycans (CSPG) could inactivate protein kinase B (Akt) and activate GSK-3β signals in neurons. GSK-3 inactivation with pharmacologic inhibitors enhances neurite outgrowth of dorsal root ganglion neurons derived from adult mice or cerebellar granule neurons from postnatal rodents cultured on CNS inhibitors. Application of GSK-3 inhibitors stimulates axon formation and elongation of mature neurons whether in presence or absence of inhibitory substrates. Systemic application of GSK-3 inhibitor lithium to spinal cord-lesioned rats suppresses the activity of this kinase around lesion. Treatments with GSK-3 inhibitors including a clinical dose of lithium to rats with thoracic spinal cord transection or contusion injuries induce significant descending corticospinal and serotonergic axon sprouting in caudal spinal cord and promote locomotor functional recovery. Our studies suggest that GSK-3 signal is an important therapeutic target for promoting functional recovery of adult CNS injuries and that administration of GSK-3 inhibitors may facilitate the development of an effective treatment to white matter injuries including spinal cord trauma given the wide use of lithium in humans.
- Funded by:
- Paralyzed Veterans of America
The temporal expression of S100B and GFAP in cerebrospinal fluid following acute human spinal cord injury (Cody M Mann)
Background: Glial fibrillary acidic protein (GFAP) and S100B have been used as biological markers of injury severity in traumatic brain injury. However, little is known about the temporal release of GFAP and S100B after spinal cord injury in humans or about the correlation of these protein levels with injury severity.
Objective: To evaluate the concentration of S100B and GFAP within the cerebrospinal fluid (CSF) of human patients with acute SCI, and document the temporal pattern of change over 72 hours.
Methods: Human patients within 48 hours of sustaining an SCI were enrolled in a clinical trial in which a lumbar intrathecal catheter was inserted to drain CSF. CSF samples were drawn at 8 hour intervals, centrifuged, and frozen at the bedside. The drains were left in for 72 hours. An ELISA kit was used to evaluate the level of S100B and GFAP in the CSF.
Results: S100B and GFAP were elevated within 24 hours after SCI. The concentrations of these factors decreased over the 72 hours that the drain was inserted.
Discussion: This study describes the temporal release of S100B and GFAP after human spinal cord injury. This information may serve as a tool to help with the classification of injury severity and prediction of neurologic outcome, and may also be useful as a biological method of monitoring the effect of drug therapies for SCI.
- Funded by:
- Vancouver Coastal Health Research Institute
- Rick Hansen Man in Motion Research Foundation
- Michael Smith for Health Research
- Paralyzed Veterans of America
Increased expression of 5'-ectonucleotidase and the adenosine A2B receptor in chronic spinal cord injury (Raymond J Grill)
Trauma to the spinal cord destroys or alters tissue through mechanical and biochemical mechanisms. These injury-induced alterations in the neuronal, glial and vascular environment include glial scarring, failed regenerative growth of motor pathways and the potential for development of devastating neuropathic pain conditions. Nucleotides and nucleosides are important mediators of cellular activity in both normal and pathological conditions. Adenosine is one such modulator that is normally present in low concentrations in the extracellular space where it acts through four G-protein-linked receptors. Injury has been shown to significantly elevate extracellular levels of adenosine through several mechanisms including the metabolism of cell-released ATP via enzymes called ectonucleotidases, the release of intracellular stores through specific transporters, and uncontrolled release through membrane disruption. Following injury, the role of adenosine has generally been considered to be benign; producing neuroprotective effects. However, injury-induced adenosine has also been linked with astroglial activation, influencing astrocyte proliferation and morphological characteristics of gliosis (Liberto et al. 2004). Adenosine levels increase dramatically, but transiently, following SCI (McAdoo et al, 2000), hitting a peak between 30 to 60 minutes post-injury, then returning to baseline levels. Despite the transient increase in adenosine following SCI, we have recently detected elevated immunoreactivity (-IR) of the low-affinity adenosine A2B receptor co-localized with the astrocytic marker GFAP in- and around the site of spinal contusion in adult rats one-to-three months post-SCI. A2B-IR was also detected in cells of the central canal bordering the cavity. Interestingly, A2B+/GFAP+ cells appear to stream from the canal region to the contusion cavity. Elevated 5’-ectonucledotidase (5-NT)-IR co-localized to both reactive astrocytes and blood vessels in- and around the lesion cavity in chronic SCI. While the presence of elevated extracellular adenosine has yet to be demonstrated in the chronically-injured cord, our current data suggest that adenosine may play a role in influencing pathological processes such as the glial scar in chronic SCI.
- Funded by:
- NIH Grant NS049409
- Paralyzed Veterans of America #2511
- Mission Connect, a project of the TIRR Foundation
Comment